Clinical trial
Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin…
NCT00038948 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00038948 |
|---|---|
| Title | Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients |
| Official title | A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Renal Transplantation |
| Intervention type | Drug |
| Interventions | Sirolimus, tacrolimus, Cyclosporine A |
| Enrollment | 830 |
| Start date | Jan 1, 2002 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jun 7, 2002 |
| Last update posted | May 14, 2010 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: